Last reviewed · How we verify
NCT00540397
Traditional Chinese Medicine Etiological Study on the Theory of XuSunShengJi in Liver Cirrhosis
NA trial testing Fuzhenghuayu Tablet, Huangqi Decoction Granule in Liver Cirrhosis. Status unknown.
Quick facts
| Lead sponsor | Shanghai University of Traditional Chinese Medicine |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Sites | 1 location across China |
Drugs / interventions tested
- Fuzhenghuayu Tablet, Huangqi Decoction Granule — full drug profile →
Conditions studied
- Liver Cirrhosis — all drugs for Liver Cirrhosis →
Sponsor
Shanghai University of Traditional Chinese Medicine
Who can join
Adults 18 to 65, any sex, with Liver Cirrhosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To Elucidate and Confirm the Theory of XuSunShengJi in the Traditional Chinese Medicine Etiological Pathogenesis of Liver Cirrhosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting Hepatic Stellate Cells for the Treatment of Liver Fibrosis by Natural Products: Is It the Dawning of a New Era?
Chan YT, Wang N, Tan HY, Li S, et al · · 2020 · cited 37× · PMID 32425789 · DOI 10.3389/fphar.2020.00548
Verify or expand the search:
- PubMed search for NCT00540397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Cirrhosis
Currently open trials in the same condition.
- NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
- NCT07325526 — A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- · Phase 2 · recruiting
- NCT07418008 — The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) · recruiting
- NCT07201649 — Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcificati · NA · recruiting
- NCT07252102 — Effect of HFNC on Incidence of Hypoxia During Sedated Gastrointestinal Endoscopy in Critical Patients · NA · recruiting
Other Shanghai University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07331740 — Development and Application of a Parenting Anxiety Intervention Program for Young and Middle-Aged Female Breast Cancer P · NA · not yet recruiting
- NCT07069049 — Electroacupuncture in the Treatment of Patients Undergoing Transperineal Prostate Biopsy Under Local Anesthesia · NA · not yet recruiting
- NCT07245342 — Electroacupuncture for Improving Urinary Incontinence After Radical Prostatectomy · NA · not yet recruiting
- NCT06921512 — TCM Daoyin for Anxiety/Depression: Psychological Effects and Biological Mechanisms · NA · recruiting
- NCT06690606 — EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00540397 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai University of Traditional Chinese Medicine
- Last refreshed: 5 October 2007
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00540397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing